Article Title: Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19
Figure Lengend Snippet: A] Cell viability after incubation of Vero cells with imatinib for either 1 or 8 hours. and B] SARS-CoV-2 neutralization profile post 1- and 8-hours exposure to imatinib. Inhibition of VSV pseudoparticles for SARS-CoV, SARS-CoV-2, MERS-CoV and VSV(control) after incubation with imatinib in C] Vero cells and D] Vero-TMPRSS2 cells. The red arrow indicates the concentration where no toxicity was observed microscopically anymore (15 nM). E] The association and dissociation curves obtained by BLI reflecting the binding of imatinib (0.78 to 6.25 µM) to immobilized SARS-CoV-2 RBD protein. Data fitted using the 1:1 binding model are shown in black.
Article Snippet: BLIThe binding kinetics of imatinib on SARS-CoV-2 RBD protein were studied using a BLItz® system (FortéBio).
Techniques: Incubation, Neutralization, Inhibition, Concentration Assay, Binding Assay